查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
检体采集卡市场：2023年至2028年预测
市场调查报告书
商品编码
1410144

检体采集卡市场：2023年至2028年预测

Specimen Collection Cards Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

检体采集卡市场预计在预测期内复合年增长率为 5.87%。

检体采集卡是为了方便血液、唾液、口腔细胞、尿液等各种生物样本的采集和运输而特意製作的。它在保持 DNA 完整性方面也非常出色，即使在常温下长期保存后也能确保 DNA 的快速洗脱。检体卡采集的应用涵盖广泛的领域，包括新生儿筛检(NBS)、传染病检查、治疗药物监测、法医学、研究、福祉/健康监测以及各种其他应用。

病理学的进步将推动检体采集卡市场的成长。

检体采集卡因其方便有效地保存血液、唾液、口腔细胞、尿液等各种生物样本而被医学实验室和病理学科学家广泛使用。这些卡可实现安全高效的样本采集、运输和存储，使其成为诊断测试的重要工具。对检体采集卡的需求不断增加，因为越来越多的不同领域的科学家认识到这些卡的价值，包括非侵入性采样和可靠的 DNA 洗脱。例如，2020年，加拿大医学和病理科学家人数激增至19,757人，与前一年同期比较大幅增加6.8%。

法医学中心设施正在推动检体采集卡市场的发展。

法医学中心使用检体采集卡在安全储存和运输从犯罪现场、受害者和嫌疑人收集的生物证据方面发挥重要作用。这些卡片可以轻鬆、非侵入性地对血液、唾液和其他体液进行采样，确保 DNA 和其他生物标记物的完整性，从而实现准确的分析和证据记录。由于刑事调查对科学进步的需求不断增加，法医学中心正在快速发展。据内政部称，2023年5月，印度政府在古瓦哈提建立了第10个国家法医学大学（NFSU）中心，使其成为全球第11个中心。

政府的措施和投资正在推动检体采集卡市场的发展。

由于政府旨在改善医疗服务和加强疾病早期检测的诊断中心的倡议和投资，检体采集卡行业取得了显着增长。检体采集卡在这些情况下发挥重要作用，因为它们可以实现高效可靠的样本采集并确保诊断测试的准确性。例如，2021年11月，英国政府向NHS拨款约3.37亿美元资金，专门用于加强诊断服务的技术基础设施。这项投资的主要目标是简化 NHS 内订购、进行和审查医疗检查的整个流程。

预计亚太地区将主导市场。

由于病理学研究人员数量大幅增加以及对可靠、高效的检体采集方法的需求急剧增加，亚太地区在检体采集卡市场中占据了主要份额。例如，根据世界卫生组织（WHO）统计，2020年，印度医学和病理科学家人数激增至635,500人，较2018年大幅增加65%。此外，该地区各国政府正在进行大量投资，以提高诊断中心的能力并加强医疗基础设施。例如，2020年6月，中国当局发起一项倡议，采集全国7亿男性和女性的血液样本并建立基因资料库。

替代样本的存在限制了检体采集卡市场的成长。

来自液体采集系统和自动采样设备等替代样本采集方法的激烈竞争正在限制检体采集卡行业的成长。由于这些替代方案具有多种优势，包括易于使用、提高通量以及适合特定分析物，因此医学和研究界的偏好可能会发生变化，对检体采集卡的需求也可能会发生变化，这可能会影响整体。

企业产品

  • EasiCollect Plus： QIAGEN 推出了 EasiCollect Plus，这是一款先进的口腔样本采集设备，具有整合的可闭合设计，可确保一致且可靠的样本传输，同时提供安全运输。这种先进的解决方案提供了一种使用者友好且无缝的口腔样本采集方法，确保了运输过程中样本的完整性，并显着提高了各种应用中样本分析的准确性和效率。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
  • 产业价值链分析

第五章检体采集卡市场：依检体类型

  • 介绍
  • 血
  • 唾液
  • 尿
  • 口腔细胞
  • 其他的

第六章检体采集卡市场：依材料分类

  • 介绍
  • 棉纤维素基
  • 纤维基
  • 其他的

第七章检体采集卡市场：分产品

  • 介绍
  • Whatman 903
  • Ahlstrom 226
  • FTA
  • 其他的

第八章检体采集卡市场：依应用分类

  • 介绍
  • 新生儿筛检(NBS)
  • 传染病检查
  • 治疗药物监测
  • 法医学
  • 研究
  • 福祉/健康监测
  • 其他用途

第九章检体采集卡市场：分地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第十章竞争环境及分析

  • 主要企业及策略分析
  • 新兴企业和市场盈利
  • 合併、收购、协议和合作
  • 供应商竞赛矩阵

第十一章 公司简介

  • QIAGEN
  • PerkinElmer Inc.
  • Euroimmun
  • Eastern Business Forms, Inc.
  • Ahlstrom
  • ARCHIMED Life Science GmbH
  • GenTegra LLC
  • FortiusBio
  • CENTOGENE NV
简介目录
Product Code: KSI061615819

The specimen collection card market is estimated to grow at a CAGR of 5.87% during the forecast period.

Specimen collection cards are purposefully crafted to facilitate the collection and transportation of various bio-samples, such as blood, saliva, buccal cells, and urine. Also, they excel in preserving DNA integrity, ensuring its swift elution even after extended periods of storage at ambient temperatures. The applications of specimen card collection encompass a wide range of areas, including Newborn Screening (NBS), infectious diseases testing, therapeutic drug monitoring, forensics, research, well-being/health monitoring, and other diverse applications.

Improved pathology bolsters the specimen collection cards market growth.

Specimen collection cards are extensively used in medical laboratories and pathology by scientists due to their convenience and effectiveness in preserving various biological samples like blood, saliva, buccal cells, and urine. These cards enable safe and efficient sample collection, transportation, and storage, making them an indispensable tool for diagnostic testing purposes. The increasing demand for specimen collection cards can be attributed to the growing number of scientists engaged in diverse fields of research, who recognize the value of these cards for non-invasive sampling, and reliable DNA elution. For instance, In 2020, the number of medical and pathology scientists in Canada surged to 19,757, marking a notable 6.8% increase compared to the previous year.

Improved forensic science centres' establishments drive the specimen collection card market.

Specimen collection cards are utilized in forensic science centres for their crucial role in securely preserving and transporting biological evidence collected from crime scenes, victims, or suspects. These cards enable easy, non-invasive sampling of blood, saliva, and other bodily fluids, ensuring the integrity of DNA and other biomarkers for accurate analysis and evidence documentation. Forensic science centres are experiencing rapid growth due to increasing demand for scientific advancements in criminal investigations. According to the Ministry of Home Affairs, in May 2023, the Government of India established its 10th National Forensic Science University (NFSU) centre in Guwahati, also making it the world's 11th centre.

Government initiatives and investments drive the specimen collection cards market.

The specimen collection cards industry is experiencing significant growth driven by government initiatives and investments aimed at bolstering diagnostic centres with a focus on improving healthcare services and enhancing early disease detection. Specimen collection cards play a crucial role in this context, as they enable efficient and reliable sample collection, and ensure the accuracy of diagnostic tests. For instance, in November 2021, the UK government allocated approximately $337 million in funding to the NHS, dedicated to enhancing the technological infrastructure of its diagnostic services. The primary objective of this investment was to streamline the entire process of ordering, performing, and reviewing medical tests within the NHS (National Health Service).

Asia-Pacific is expected to dominate the market.

Asia-Pacific will hold a significant share of the specimen collection card market due to a substantial increase in the number of pathology scientists, contributing to a surge in demand for reliable and efficient sample collection methods. For instance, according to the World Health Organization, in 2020, the number of medical and pathology scientists in India surged to 635,500, marking a remarkable 65% increase from the figures recorded in 2018. Additionally, governments in the region have undertaken significant investments to boost diagnostic centres' capabilities and enhance healthcare infrastructure For instance, in June 2020, Chinese authorities launched an initiative to collect blood samples of males 700 million males including men and boys across the country to create a genetic database that would provide the government with a sophisticated tool for their advancing high-tech surveillance capabilities.

Alternatives availability restrains the specimen collection cards market growth.

The presence of stiff competition from alternative sample collection methods, including liquid-based collection systems and automated sampling devices is contracting the specimen collection cards industry growth. These alternative methods offer diverse advantages, such as enhanced ease of use, higher throughput, and compatibility with specific analytes, leading to potential shifts in preferences within the medical and research communities, which could in turn influence the overall demand for specimen collection cards.

Key Developments

  • February 2023: Capitainer AB introduced an innovative self-sampling product to the market, boasting the capability to collect five times more blood than its previous version. This advancement allows for a wider range of analyses and testing options. Additionally, the new product has been designed to be more user-friendly, simplifying the implementation process for laboratories. Its improved features hold the potential to revolutionize blood sample collection and analysis, offering enhanced efficiency and flexibility in diagnostic and research.
  • July 2022: Rhinostics introduced the revolutionary VERIstic, a groundbreaking collection device that redefines small-volume blood collection. It seamlessly combines the proven method of capillary blood collection with an integrated, automation-ready cap, streamlining the process and offering significant benefits for time, cost, and workflow efficiency in laboratories. For patients and clinicians alike, the collection procedure is now rapid, simple, and comfortable, enhancing the overall experience and facilitating a hands-free workflow from sample collection to laboratory analysis.
  • May 2022: Abson Diagnostics and Becton, Dickinson and Company (BD) have further strengthened their strategic collaboration, aiming to spearhead innovation in blood sample collection, with a specific focus on exploring new care settings. The expanded partnership aims to empower patients by allowing them to conveniently collect blood samples at home for diagnostic testing, offering greater accessibility and ease of healthcare services. This advancement promises to revolutionize the way diagnostic testing is conducted, bringing the benefits of home-based blood sample collection to patients and healthcare providers.

Company Products

  • EasiCollect Plus: QIAGEN introduces EasiCollect Plus, an advanced buccal sample collection device that boasts an integrated and closable design, ensuring both consistent and reliable sample transfer while providing secure transportation. This advanced solution offers a user-friendly and seamless approach to collecting buccal samples, guaranteeing their integrity during transportation, and significantly improving the precision and efficiency of sample analysis across a range of applications.

Segmentation

By Type of Specimen

  • Blood
  • Saliva
  • Urine
  • Buccal Cells
  • Others

By Material

  • Cotton & Cellulose-based
  • Fiber-based
  • Others

By Product

  • Whatman 903
  • Ahlstrom 226
  • FTA
  • Others

By Application

  • New Born Screening (NBS)
  • Infectious Diseases Testing
  • Therapeutic Drug Monitoring
  • Forensics
  • Research
  • Wellbeing/Health Monitoring
  • Other Applications

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. SPECIMEN COLLECTION CARDS MARKET, BY TYPE OF SPECIMEN

  • 5.1. Introduction
  • 5.2. Blood
  • 5.3. Saliva
  • 5.4. Urine
  • 5.5. Buccal Cells
  • 5.6. Others

6. SPECIMEN COLLECTION CARDS MARKET, BY MATERIAL

  • 6.1. Introduction
  • 6.2. Cotton & Cellulose-based
  • 6.3. Fiber-based
  • 6.4. Others

7. SPECIMEN COLLECTION CARDS MARKET, BY PRODUCT

  • 7.1. Introduction
  • 7.2. Whatman 903
  • 7.3. Ahlstrom 226
  • 7.4. FTA
  • 7.5. Others

8. SPECIMEN COLLECTION CARDS MARKET, BY APPLICATION

  • 8.1. Introduction
  • 8.2. New Born Screening (NBS)
  • 8.3. Infectious Diseases Testing
  • 8.4. Therapeutic Drug Monitoring
  • 8.5. Forensics
  • 8.6. Research
  • 8.7. Wellbeing/Health Monitoring
  • 8.8. Other Applications

9. SPECIMEN COLLECTION CARDS MARKET, BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. United States
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. United Kingdom
    • 9.4.2. Germany
    • 9.4.3. France
    • 9.4.4. Spain
    • 9.4.5. Others
  • 9.5. The Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Israel
    • 9.5.4. Others
  • 9.6. Asia Pacific
    • 9.6.1. Japan
    • 9.6.2. China
    • 9.6.3. India
    • 9.6.4. South Korea
    • 9.6.5. Indonesia
    • 9.6.6. Thailand
    • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Emerging Players and Market Lucrativeness
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Vendor Competitiveness Matrix

11. COMPANY PROFILES

  • 11.1. QIAGEN
  • 11.2. PerkinElmer Inc.
  • 11.3. Euroimmun
  • 11.4. Eastern Business Forms, Inc.
  • 11.5. Ahlstrom
  • 11.6. ARCHIMED Life Science GmbH
  • 11.7. GenTegra LLC
  • 11.8. FortiusBio
  • 11.9. CENTOGENE N.V.